ARIAD begin Phase II study of Deforolimus in Prostate Cancer

ARIAD/Merck have initiated a Phase II clinical trial to evaluate the safety and efficacy of mTOR inhibitor deforolimus in patients with advanced prostate cancer.

Pfizer to present data on JAK-inhibitor CP-690,550 at ACR meeting

Pfizer will be presenting Phase 2b data on investigational JAK-inhibitor CP-690,550 at the forthcoming ACR meeting:

Imatinib shows potential in pulmonary arterial hypertension (PAH)

Phase II data presented at the European Respiratory Society show Imatinib to demonstrate efficacy in the treatment of pulmonary arterial hypertension (PAH).

ArQule Achieves Clinical Milestone with ARQ 197 in MiT tumors

ArQule have announced that it will expand its Phase II trial with c-Met inhibitor ARQ 197 in MiT (Microphthalmia Transcription Factor)-associated tumors after achieving a partial response in a patient with clear cell sarcoma.

ImClone initiate randomized Phase II trial of IMC-A12 in breast cancer

ImClone Systems have initiated a phase II clinical trial of its anti-IGF-1R MAb IMC-A12 in women with advanced breast cancer

Thallion present data on M2PK inhibitor TLN-232

Data presented at the European Society of Medical Oncology (ESMO) show Thallion Pharmaceutical’s M2PK inhbitor  TLN-232 to be effective in a Phase II trial in renal cancer

Roche to present at ESMO

Roche have announced that 100+ abstracts on Roche medicines will be presented at the upcoming European Society for Medical Oncology (ESMO) meeting.

Key presentations include:
* Data from AVAiL, confirming the use of Avastin as first line treatment in NSCLC
* Phase III data on continuation of Herceptin treatment
* Phase II data data on the use of [...]

VEGF-Trap effective in Phase II AMD trial

Phase II data released by Bayer and Regeneron show VEGF Trap-Eye is effective in patients with wet age-related macular degeneration (AMD).

AstraZeneca initiate Phase I/II trial of mTOR inhibitor AZD8055

AstraZeneca have initiated a Phase I/II trial of mTOR inhibitor AZD8055 in Advance Solid Tumors, Lymphoma and Endometrial Carcinoma

ARIAD initiate Phase II trial of deforolimus in Endometrial Cancer

ARIAD Pharmaceuticals have announced the initiation of a phase II clinical trial of mTOR inhibitor deforolimus in patients with advanced endometrial cancer.